• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从发病机制到治疗方法:斑秃免疫病理学的当前进展与突破

From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.

作者信息

Zhao Huai-Bo, Zhang Ya-Nan, Qiang Yan, Wang Guo-Mi, Wang Li-Wei, Jiang Wen-Cheng, Chen Xi

机构信息

Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.

Eight Departments of Traditional Chinese Medicine Surgery, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

出版信息

Front Immunol. 2025 Sep 1;16:1621492. doi: 10.3389/fimmu.2025.1621492. eCollection 2025.

DOI:10.3389/fimmu.2025.1621492
PMID:40959061
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12433866/
Abstract

Alopecia areata (AA) is a prevalent autoimmune condition characterized by hair loss, with the collapse of hair follicle immune privilege being a pivotal event in its pathogenesis. This collapse involves intricate immunological disturbances, where CD8NKG2D T cells, driven by inflammatory cytokines like IFN-γ, attack hair follicles. Additionally, various immune cell, including Th1, Th2, Th17 cells, γδT cells, NK cells, and mast cells, contribute to this pathological process. Defects in the function of Tregs, Bregs, and iNKT cells further compound the immune imbalance. At the molecular level, the JAK-STAT pathway emerges as a central regulatory node integrating multiple cytokine signals and presenting itself as a significant therapeutic target. JAK inhibitors have shown notable effectiveness in clinical settings, with some agents even gaining FDA approval for treating moderate-to-severe AA. However, the effectiveness of targeting IL-17, TNF-α, Th2 cytokines, PDE4, and other molecules remains debated. This review comprehensively explores the dynamic interactions among immune cell subsets, cytokine networks, and crucial signaling pathways in AA pathogenesis. It also summarizes the latest clinical progress and challenges in targeted therapies. Future studies should delve deeper into AA's immune regulatory framework and devise tailored treatment approaches to enhance patient outcomes.

摘要

斑秃(AA)是一种常见的自身免疫性疾病,其特征为脱发,毛囊免疫豁免的崩溃是其发病机制中的关键事件。这种崩溃涉及复杂的免疫紊乱,其中由IFN-γ等炎性细胞因子驱动的CD8⁺NKG2D⁺ T细胞会攻击毛囊。此外,包括Th1、Th2、Th17细胞、γδT细胞、NK细胞和肥大细胞在内的各种免疫细胞也参与了这一病理过程。调节性T细胞(Tregs)、调节性B细胞(Bregs)和不变自然杀伤T细胞(iNKT细胞)的功能缺陷进一步加剧了免疫失衡。在分子水平上,JAK-STAT信号通路是整合多种细胞因子信号的核心调节节点,也是一个重要的治疗靶点。JAK抑制剂在临床环境中已显示出显著疗效,一些药物甚至已获得美国食品药品监督管理局(FDA)批准用于治疗中度至重度斑秃。然而,针对白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)、Th2细胞因子、磷酸二酯酶4(PDE4)和其他分子的治疗效果仍存在争议。本综述全面探讨了斑秃发病机制中免疫细胞亚群、细胞因子网络和关键信号通路之间的动态相互作用。它还总结了靶向治疗的最新临床进展和挑战。未来的研究应更深入地探究斑秃的免疫调节框架,并设计出量身定制的治疗方法以改善患者预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66ff/12433866/a63368f36628/fimmu-16-1621492-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66ff/12433866/a63368f36628/fimmu-16-1621492-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/66ff/12433866/a63368f36628/fimmu-16-1621492-g001.jpg

相似文献

1
From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.从发病机制到治疗方法:斑秃免疫病理学的当前进展与突破
Front Immunol. 2025 Sep 1;16:1621492. doi: 10.3389/fimmu.2025.1621492. eCollection 2025.
2
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.评估斑秃的现有和新型JAK抑制剂:一项叙述性综述
Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib.斑秃患者眉毛和睫毛受累情况及巴瑞替尼治疗反应的研究
Br J Dermatol. 2025 Apr 3. doi: 10.1093/bjd/ljaf088.
5
Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata.口服酪氨酸激酶3/肝细胞癌中表达的酪氨酸激酶家族激酶抑制剂芦可替尼24个月的疗效和安全性:斑秃的ALLEGRO IIb/III期和长期III期临床研究的综合分析
Br J Dermatol. 2025 Jan 24;192(2):215-227. doi: 10.1093/bjd/ljae365.
6
A meta-analysis of chemokines in alopecia areata: recruiting immune cells toward the hair follicle.斑秃中趋化因子的荟萃分析:将免疫细胞招募至毛囊
Front Immunol. 2025 Sep 3;16:1648868. doi: 10.3389/fimmu.2025.1648868. eCollection 2025.
7
Coexistence of bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata: a case report of multifactorial autoimmunity in a surgical context.大疱性类天疱疮、肝内胆管癌和斑秃并存:手术背景下多因素自身免疫的病例报告
Front Immunol. 2025 Aug 21;16:1650253. doi: 10.3389/fimmu.2025.1650253. eCollection 2025.
8
Hair follicle immune privilege and its collapse in alopecia areata.毛发滤泡免疫豁免及其在斑秃中的崩溃。
Exp Dermatol. 2020 Aug;29(8):703-725. doi: 10.1111/exd.14155.
9
Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment.特应性皮炎和斑秃的重叠特征:从发病机制到治疗
Front Immunol. 2025 Sep 3;16:1641918. doi: 10.3389/fimmu.2025.1641918. eCollection 2025.
10
Treatments for alopecia areata: a network meta-analysis.斑秃治疗方法的网状荟萃分析。
Cochrane Database Syst Rev. 2023 Oct 23;10(10):CD013719. doi: 10.1002/14651858.CD013719.pub2.

本文引用的文献

1
Complete hair regrowth in a patient with severe alopecia areata treated with deucravacitinib.
Clin Exp Dermatol. 2025 Jul 29. doi: 10.1093/ced/llaf345.
2
Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients.
Indian J Dermatol Venereol Leprol. 2025 Mar 24:1-5. doi: 10.25259/IJDVL_1755_2024.
3
Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report.中国产托法替布治疗斑秃的显著疗效:一例报告
Front Immunol. 2025 Apr 11;16:1553904. doi: 10.3389/fimmu.2025.1553904. eCollection 2025.
4
Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients.斑秃患者中JAK抑制剂的真实世界有效性和安全性:一项对72例患者的回顾性队列研究
Acta Derm Venereol. 2025 Apr 7;105:adv42990. doi: 10.2340/actadv.v105.42990.
5
A Novel Topical Compound Gel Loading Minoxidil and Tofacitinib for Treatment of Alopecia Areata: Formulation, Characterization, and In Vitro/In Vivo Evaluation.一种用于治疗斑秃的新型局部复方凝胶,负载米诺地尔和托法替布:制剂、表征及体外/体内评价
Drug Dev Res. 2025 Apr;86(2):e70076. doi: 10.1002/ddr.70076.
6
Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.利特昔替尼在亚洲斑秃患者中的疗效和安全性:ALLEGRO 2b/3期试验的亚组分析
J Dermatol. 2025 Apr;52(4):603-614. doi: 10.1111/1346-8138.17539. Epub 2025 Mar 12.
7
IKZF1 and Ikaros Overexpression Results in Alopecia Areata-Like Phenotype in Mice.IKZF1和Ikaros过表达导致小鼠出现斑秃样表型。
Exp Dermatol. 2025 Mar;34(3):e70074. doi: 10.1111/exd.70074.
8
Epidemiology of Pediatric Alopecia Areata.儿童斑秃的流行病学
Pediatr Dermatol. 2025 Mar;42 Suppl 1(Suppl 1):12-23. doi: 10.1111/pde.15803.
9
Comparative Efficacy of Intralesional Steroid Injections vs Cryotherapy for the Treatment of Alopecia Areata.
J Drugs Dermatol. 2025 Mar 1;24(3):294-297. doi: 10.36849/JDD.8499.
10
Global Burden of Alopecia Areata and Associated Diseases: A Trend Analysis From 1990 to 2021.斑秃及相关疾病的全球负担:1990年至2021年的趋势分析
J Cosmet Dermatol. 2025 Mar;24(3):e70076. doi: 10.1111/jocd.70076.